VLX600
目录号 : KM5126 CAS No. : 327031-55-0 纯度 : 98%

VLX600 是氧化磷酸化 (OXPHOS) 的铁螯合抑制剂。VLX600 导致线粒体功能障碍,并导致向糖酵解的强烈转变。VLX600 对恶性细胞表现出选择性的细胞毒活性,并诱导自噬 (autophagy)。具有抗癌活性。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
25mg
In-stock
50mg
In-stock
100mg
In-stock
250mg
In-stock
500mg 询价 In-stock
1g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

VLX600 is an iron-chelating inhibitor of oxidative phosphorylation (OXPHOS). VLX600 causes mitochondrial dysfunction and induces a strong shift to glycolysis. VLX600 displays selective cytotoxic activity against malignant cell and induces autophagy. Anticancer activity.

体外研究

VLX600 (6 μM; 72 hours) induces an autophagic response.
VLX600 is cytotoxic to HCT116 spheroids. VLX600 induces a HIF-1α-dependent glycolytic response. VLX600 inhibits oxygen consumption in HCT116 cells. VLX600 inhibits phosphorylation of the mTOR downstream effectors 4EBP1 and p70-S6K by an HIF-1α-independent mechanism. VLX600 preferentially leads to decreased ATP levels in cancer but not normal cells.

Cell Proliferation Assay

Cell Line: HCT116, HT29, SW620, HT8, DLD and RKO cells
Concentration: 0.1, 1, 10, 100μM
Incubation Time: 72 hours
Result: Inhibited the proliferation of these cells.

Western Blot Analysis

Cell Line: HCT116 cells
Concentration: 6 μM
Incubation Time: 72 hours
Result: LC3-II was induced.
体内研究

VLX600 (16 mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.

Animal Model: NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)
Dosage: 16 mg/kg
Administration: Intravenously; every third day for 16 days
Result: Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.
分子式
C17H15N7
分子量
317.35
CAS号
327031-55-0
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro: 

DMSO : 25 mg/mL (78.78 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1511 mL 15.7555 mL 31.5110 mL
5 mM 0.6302 mL 3.1511 mL 6.3022 mL
10 mM 0.3151 mL 1.5755 mL 3.1511 mL
*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: 2.08 mg/mL (6.55 mM); Clear solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (6.55 mM) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

临床试验
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号